These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 26555014)

  • 21. Discovery of highly potent small molecule Hepatitis C Virus entry inhibitors.
    Mittapalli GK; Jackson A; Zhao F; Lee H; Chow S; McKelvy J; Wong-Staal F; Macdonald JE
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6852-5. PubMed ID: 21978675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Secreted Interferon-Inducible Factors Restrict Hepatitis B and C Virus Entry In Vitro.
    Xia Y; Cheng X; Blossey CK; Wisskirchen K; Esser K; Protzer U
    J Immunol Res; 2017; 2017():4828936. PubMed ID: 28367455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Antiviral activity in vitro and pharmacokinetics of HCV entry inhibitor AVR560].
    Ivashchenko AV; Iamanushkin PM; Mit'kin OD; Ezhova EV; Korzinov OM; Bulanova EA; Koriakova AG; Vyshemirskaia PV; Bychko VV; Ivashchenko AA
    Eksp Klin Farmakol; 2014; 77(10):38-43. PubMed ID: 25518527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C virus entry.
    Zeisel MB; Felmlee DJ; Baumert TF
    Curr Top Microbiol Immunol; 2013; 369():87-112. PubMed ID: 23463198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of a Potent and Broad-Spectrum Hepatitis C Virus Fusion Inhibitory Peptide from the E2 Stem Domain.
    Chi X; Niu Y; Cheng M; Liu X; Feng Y; Zheng F; Fan J; Li X; Jin Q; Zhong J; Li YP; Yang W
    Sci Rep; 2016 Apr; 6():25224. PubMed ID: 27121372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Specific inhibition of hepatitis C virus entry into host hepatocytes by fungi-derived sulochrin and its derivatives.
    Nakajima S; Watashi K; Kamisuki S; Tsukuda S; Takemoto K; Matsuda M; Suzuki R; Aizaki H; Sugawara F; Wakita T
    Biochem Biophys Res Commun; 2013 Nov; 440(4):515-20. PubMed ID: 24099774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiviral activity of cuprous oxide nanoparticles against Hepatitis C Virus in vitro.
    Hang X; Peng H; Song H; Qi Z; Miao X; Xu W
    J Virol Methods; 2015 Sep; 222():150-7. PubMed ID: 26116793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitory Effects of Amentoflavone and Orobol on Daclatasvir-Induced Resistance-Associated Variants of Hepatitis C Virus.
    Lee WP; Lan KL; Liao SX; Huang YH; Hou MC; Lan KH
    Am J Chin Med; 2018; 46(4):835-852. PubMed ID: 29737209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. (-)-Epigallocatechin-3-gallate inhibits the replication cycle of hepatitis C virus.
    Chen C; Qiu H; Gong J; Liu Q; Xiao H; Chen XW; Sun BL; Yang RG
    Arch Virol; 2012 Jul; 157(7):1301-12. PubMed ID: 22491814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Research on hepatitis C virus entry inhibitor].
    Zeng Wenting ; Lu X; Wang J; Jin X; Zhu J
    Bing Du Xue Bao; 2015 Jan; 31(1):97-105. PubMed ID: 25997338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Membrane Fusion Assays for Studying Entry Hepatitis C Virus into Cells.
    Denolly S; Cosset FL; Freitas N
    Methods Mol Biol; 2019; 1911():219-234. PubMed ID: 30593629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors.
    Banda DH; Perin PM; Brown RJP; Todt D; Solodenko W; Hoffmeyer P; Kumar Sahu K; Houghton M; Meuleman P; Müller R; Kirschning A; Pietschmann T
    J Hepatol; 2019 Jun; 70(6):1082-1092. PubMed ID: 30769006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and biological evaluation of novel pentacyclic triterpene α-cyclodextrin conjugates as HCV entry inhibitors.
    Xiao S; Wang Q; Si L; Zhou X; Zhang Y; Zhang L; Zhou D
    Eur J Med Chem; 2016 Nov; 124():1-9. PubMed ID: 27565552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cellular receptors and HCV entry.
    Flint M; Tscherne DM
    Methods Mol Biol; 2009; 510():265-77. PubMed ID: 19009268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The hepatitis C virus life cycle as a target for new antiviral therapies.
    Pawlotsky JM; Chevaliez S; McHutchison JG
    Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel Arenavirus Entry Inhibitors Discovered by Using a Minigenome Rescue System for High-Throughput Drug Screening.
    Rathbun JY; Droniou ME; Damoiseaux R; Haworth KG; Henley JE; Exline CM; Choe H; Cannon PM
    J Virol; 2015 Aug; 89(16):8428-43. PubMed ID: 26041296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Viral entry inhibition: too late for hepatitis C, but promising for other viral infections.
    Pawlotsky JM
    Gut; 2015 Mar; 64(3):362-4. PubMed ID: 25098973
    [No Abstract]   [Full Text] [Related]  

  • 38. Curcumin against hepatitis C virus infection: spicing up antiviral therapies with 'nutraceuticals'?
    Pécheur EI
    Gut; 2014 Jul; 63(7):1035-7. PubMed ID: 24092864
    [No Abstract]   [Full Text] [Related]  

  • 39. Development of a robust luciferase reporter 1b/2a hepatitis C virus (HCV) for characterization of early stage HCV life cycle inhibitors.
    Chan K; Robinson M; Yang H; Cornew S; Delaney Iv WE
    Antiviral Res; 2013 Apr; 98(1):85-92. PubMed ID: 23376631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ["Entry inhibitors" prevent virus access to the cell]].
    Fessler B
    MMW Fortschr Med; 2015 Mar; 157 Suppl 1():86. PubMed ID: 26012995
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.